Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies
- PMID: 10102408
- DOI: 10.1212/wnl.52.5.932
Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies
Abstract
Objective: To use PET to study striatal dopaminergic function in restless legs syndrome (RLS).
Background: RLS is a common disorder experienced by as much as 5% of the population. It has been suggested that this condition is associated with a disturbance of dopaminergic transmission.
Methods: The authors measured nigrostriatal terminal dopamine storage with 18F-dopa and striatal D2 receptor binding with 11C-raclopride PET in 13 RLS patients, five of whom were receiving treatment with L-dopa at the time of scanning. RLS results were compared with those of age-matched control subjects.
Results: Mean caudate and putamen 18F-dopa uptake were mildly reduced in the RLS patients compared with control subjects, and this reached significance (p = 0.04) in the putamen. Mean D2 binding was reduced in the caudate (p = 0.01) and the putamen (p = 0.008) in RLS patients compared with control subjects. Six of the 13 RLS patients had caudate and putamen D2 binding reduced below the control range. Three other RLS patients showed only reduced putamen D2 binding. There were no significant differences in striatal 18F-dopa uptake or D2 binding between L-dopa-naive and L-dopa-treated RLS patients.
Conclusions: These PET findings support the hypothesis of central dopaminergic dysfunction in RLS.
Similar articles
-
Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.Arch Neurol. 1995 Dec;52(12):1183-90. doi: 10.1001/archneur.1995.00540360061017. Arch Neurol. 1995. PMID: 7492293
-
Asymmetrical pre-synaptic and post-synpatic changes in the striatal dopamine projection in dopa naïve parkinsonism. Diagnostic implications of the D2 receptor status.Brain. 1993 Aug;116 ( Pt 4):853-67. doi: 10.1093/brain/116.4.853. Brain. 1993. PMID: 8353712
-
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.Brain. 2006 Aug;129(Pt 8):2017-28. doi: 10.1093/brain/awl163. Epub 2006 Jul 1. Brain. 2006. PMID: 16816393
-
[Nightly myoclonus syndrome (NMS) and restless legs syndrome (RLS)--review and case report].Fortschr Neurol Psychiatr. 1994 Mar;62(3):88-93. doi: 10.1055/s-2007-996659. Fortschr Neurol Psychiatr. 1994. PMID: 8181789 Review. German.
-
Connectome and molecular pharmacological differences in the dopaminergic system in restless legs syndrome (RLS): plastic changes and neuroadaptations that may contribute to augmentation.Sleep Med. 2017 Mar;31:71-77. doi: 10.1016/j.sleep.2016.06.003. Epub 2016 Jun 27. Sleep Med. 2017. PMID: 27539027 Free PMC article. Review.
Cited by
-
Do you have restless leg syndrome? I understood from your eyes.Sleep Breath. 2019 Jun;23(2):551-557. doi: 10.1007/s11325-018-1740-5. Epub 2018 Oct 19. Sleep Breath. 2019. PMID: 30341586
-
Sleep disorders in Parkinson's disease.Neuropsychiatr Dis Treat. 2009;5:535-40. doi: 10.2147/ndt.s4578. Epub 2009 Nov 2. Neuropsychiatr Dis Treat. 2009. PMID: 19898667 Free PMC article.
-
The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome.Sleep. 2011 Mar 1;34(3):341-7. doi: 10.1093/sleep/34.3.341. Sleep. 2011. PMID: 21358851 Free PMC article.
-
Restless legs syndrome: pathophysiology, diagnosis and treatment.CNS Drugs. 2008;22(6):497-518. doi: 10.2165/00023210-200822060-00004. CNS Drugs. 2008. PMID: 18484792 Review.
-
The Role of BTBD9 in the Cerebellum, Sleep-like Behaviors and the Restless Legs Syndrome.Neuroscience. 2020 Aug 1;440:85-96. doi: 10.1016/j.neuroscience.2020.05.021. Epub 2020 May 22. Neuroscience. 2020. PMID: 32446853 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical